-
Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'
Thursday, August 25, 2016 - 3:52pm | 367Read More...Janney started coverage of Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) with a Neutral rating, citing potential competition to its blockbuster narcolepsy franchise. Jazz's history was based on the growth of narcolepsy drug Xyrem, but its future is dependent upon the success of...
-
Cynapsus Therapeutics Developing New Parkinson's Treatment That Won't Require Injection
Wednesday, June 15, 2016 - 4:07pm | 186Read More...Janney's Ken Trbovich initiated a Buy rating on Cynapsus Therapeutics Inc (Nasdaq: CYNA) and set a price target of $24. The company has successfully developed and marketed Apomorphine (APO) for 20 years to combat Parkinson's disease in Europe and the US. A relatively big drawback for...
-
UPDATE: MLV & Co Initiates Coverage On Flexion Therapeutics On Multiple Positive Factors
Tuesday, March 31, 2015 - 7:36am | 143Read More...In a report published Tuesday, MLV & Co analyst Ken Trbovich initiated coverage on Flexion Therapeutics, Inc. (NASDAQ: FLXN) with a Buy rating and $38.00 price target. In the report, MLV & Co noted, "Flexion's stock has performed well since its IPO last year, but we think it is far from...
